SuperworthLarimar Therapeutics LRMR
- Market cap
- $244.1M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $6.6M+18% | $10.6M+48% | $12.9M+184% | $19.7M+235% | $13.9M+111% | $26.7M+151% | $26.6M+105% | $23.4M+19% | $44.9M+223% | $59.4M+122% | $25M−6% | $28M+20% |
| SG&A | $3.8M+28% | $3.5M+9% | $3.8M+23% | $4.9M+31% | $4.3M+16% | $4.6M+30% | $4.6M+22% | $4.4M−10% | $4.6M+5% | $4.6M+2% | $6.1M+31% | $6.4M+44% |
| −$10.3M+21% | −$14.2M+36% | −$16.7M+119% | −$24.6M+156% | −$18.3M+77% | −$31.3M+121% | −$31.2M+86% | −$27.8M+13% | −$49.5M+171% | −$64M+105% | −$31.1M−0% | −$34.4M+24% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$9.1M+9% | −$13M+38% | −$14.7M+125% | −$21.6M+159% | −$15.5M+71% | −$28.8M+122% | −$29.3M+100% | −$26.2M+21% | −$47.7M+208% | −$62.5M+117% | −$29.6M+1% | −$32.8M+25% |
| −$0.21−43% | −$0.30+43% | −$0.27+80% | −$0.34+79% | −$0.24+14% | −$0.45+50% | −$0.46+70% | −$0.41+21% | −$0.61+154% | n/a | n/a | n/a | |
| 43.9M+98% | 43.9M+0% | 53.6M+22% | 63.8M+45% | 63.8M+45% | 63.8M+45% | 64M+19% | 64M+0% | 78.3M+23% | n/a | n/a | n/a |
R&D: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY14: 6 months less the 3 months printed beside them.
Net income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY13 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY13 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Larimar Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LRMRLarimar Therapeutics | $244.1M | n/m | n/a | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| Peer median | $570.3M | 11.3× | 13.6× | 1.4× | +7% | 13.6% |
More on Larimar Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .